VEGFA and glioma: Bevacizumab is a recombinant monoclonal antibody (bevacizumab) approved for the treatment of recurrent glioma, targeting and blocking vascular endothelial growth factor (VEGF), which is a pivotal stimulator of tumor vascularization.